Forma Therapeutics nabbed a $225m upfront fee to enter into its second collaboration with Celgene, but the agreement is structured as up to four transactions in one – the last deal being an acquisition of Forma by its partner.
Forma Therapeutics nabbed a $225m upfront fee to enter into its second collaboration with Celgene, but the agreement is structured as up to four transactions in one – the last deal being an acquisition of Forma by its partner.
Celgene entered into an initial collaboration with Watertown, Massachusetts-based Forma under the companies' new agreement, but it has an option to enter into two additional partnerships, which would give Forma up to $375m in additional upfront fees
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
